1. News from AHA.
- Subjects
- *
COST effectiveness , *ANTICOAGULANTS , *ATRIAL fibrillation treatment , *COST analysis , *SYNDROMES , *THERAPEUTICS - Abstract
The article provides an overview of three of the top pharmacoeconomic studies presented at the 834 annual scientific meeting of the American Heart Association in New Orleans, Louisiana in November 2010. The firs study revealed the cost effectiveness of fondaparinux compared with enoxaparin for treating non-ST-elevation acute pulmonary syndrome. Another study comparatively analyzed the cost and cost effectiveness of rhythm and rate control strategies in treating atrial fibrillation patients.
- Published
- 2011
- Full Text
- View/download PDF